Myeloproliferative neoplasm classification: Difference between revisions

	Myeloproliferative Neoplasm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating myeloproliferative neoplasm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myeloproliferative neoplasm classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myeloproliferative neoplasm classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myeloproliferative neoplasm classification
on Myeloproliferative neoplasm classification
Myeloproliferative neoplasm classification in the news
Blogs on Myeloproliferative neoplasm classification
Directions to Hospitals Treating Myeloproliferative neoplasm
Risk calculators and risk factors for Myeloproliferative neoplasm classification

Revision as of 23:49, 3 June 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Myeloproliferative neoplasm may be classified according to the World Health Organization into eight subtypes: chronic myelogenous leukemia, chronic neutrophilic leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, mastocytosis, and myeloproliferative neoplasms, unclassifiable.^[1]


Disease	Cell of origin	W.H.O. 2016 Diagnostic criteria

Polycythemia vera	Erythroid precursor	Major criteria: Hemoglobin > 16.5 g/dl in men or hemoglobin > 16 g/dl in women Bone marrow biopsy showing hypercellularly for age and trilineage growth (panmyelosis) Presence of JAK2 V617F or exon 12 mutation Minor criterion: Subnormal erythropoietin level Diagnosis requires meeting all 3 major criterion or 2 major plus 1 minor criterion
Essential thrombocythemia	Megakaryocyte
Primary myelofibrosis	Megakaryocyte
Chronic myeloid leukemia	Common myeloid precursor
Chronic neutrophilic leukemia	Neutrophil
Chronic eosinophilic leukemia	Eosinophil
Myeloproliferative neoplasm, unclassifiable	Variable
Mastocytosis	Mast cell

@@ Line 11: / Line 11: @@
 ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Disease}}
 ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Cell of origin}}
+! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|W.H.O. 2016 Diagnostic criteria}}
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
@@ Line 16: / Line 17: @@
 | style="padding: 5px 5px; background: #F5F5F5;" |
 Erythroid precursor
+| style="padding: 5px 5px; background: #F5F5F5;" |
+''Major criteria'':
+*Hemoglobin > 16.5 g/dl in men or hemoglobin > 16 g/dl in women
+*Bone marrow biopsy showing hypercellularly for age and trilineage growth (panmyelosis)
+*Presence of ''JAK2'' ''V617F'' or exon 12 mutation
+''Minor criterion'':
+*Subnormal erythropoietin level
+Diagnosis requires meeting all 3 major criterion or 2 major plus 1 minor criterion
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |